trending Market Intelligence /marketintelligence/en/news-insights/trending/aMoGGXZaMn-GvZttPKlLIg2 content esgSubNav
In This List

Summit Therapeutics buying UK-based Discuva for antibiotic expansion

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Summit Therapeutics buying UK-based Discuva for antibiotic expansion

Summit Therapeutics plc acquired privately held U.K.-based Discuva Ltd. to strengthen its antibiotics business.

Discuva's principal asset is a genetics-based technology platform for the generation of antibiotics.

"With the acquisition, Summit is positioned as a leader in the research and development of new classes of antibiotics as exemplified by our precision antibiotic candidate ridinilazole for the treatment of C. difficile infection," Summit CEO Glyn Edwards said in a Dec. 23 news release. "Using this platform, we aim to generate a pipeline of new mechanism of action antibiotics that address other serious infectious disease threats."

Under the merger agreement, the consideration to Discuva shareholders is made up of £5.0 million in cash and £5.0 million in new ordinary shares of Summit of one penny nominal value issued to Discuva shareholders at a price of 170.4 pence per share, representing a 3.3% premium to Summit's midmarket closing share price on Dec. 22.

Summit purchased Discuva on a cash-free/debt-free basis. No Discuva employees will be joining Summit's board.